Cover Image

Meningiomas and the tumor microenvironment: expression of PD-L1 and expression of PD-L1 and interferon-gamma in the prognosis

ABSTRACT Introduction: Meningiomas are the most common intracranial tumors in adults. One of the mechanisms used by tumor cells to escape death by immune cells is to interfere with immunological checkpoints, thereby preventing the establishment of adequate immune response. Following this concept, a...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gunter Gerson (Author), Paulo G. B. Silva (Author), Carlos Eduardo L. Soares (Author), Gabriel C. L. Chagas (Author), Amanda R. Rangel (Author), Aline K. A. Rodrigues (Author), Cleto D. Nogueira (Author), Fábio R. F. Távora (Author)
Format:	Book
Published:	Sociedade Brasileira de Patologia Clínica.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lymphoplasmacyte-rich meningioma with hematologic signs and PD-L1 over-expression
by: Gabriele Gaggero, et al.
Published: (2022)

Consistent expression of PD-L1 in tumor microenvironment with peripheral PD-1/PD-L1 in circulating T lymphocytes of operable breast cancer: a diagnostic test
by: Keyu Yuan, et al.
Published: (2022)

PD-1 and PD-L1 expression in rare lung tumors
by: Marton Gyulai, et al.
Published: (2023)

PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients
by: Jiheun Han, et al.
Published: (2017)

Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients with Psoriasis
by: Selma Emre, et al.
Published: (2023)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021)

The frequency of high PD-L1 expression is low in lung adenocarcinoma patients from Northeast Brazil
by: Antonio V. Alves da Silva, et al.
Published: (2019)

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer
by: Maureen L. Drakes, et al.
Published: (2018)

Profile of PD-1 and PD-L1 mRNA Expression in Peripheral Blood of Nasopharyngeal Carcinoma
by: Muhammad Al Al Azhar, et al.
Published: (2020)

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma
by: Yanhua Bai, et al.
Published: (2017)

GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression
by: Young Wha Koh, et al.
Published: (2017)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
by: Monika Walankiewicz, et al.
Published: (2018)

Association of PD-1/PD-L1 expression and Epstein--Barr virus infection in patients with invasive breast cancer
by: Wei-tong Zhang, et al.
Published: (2022)

PD-L1 expression in invasive solid papillary breast carcinomas
by: Sevdegul Aydın Mungan, et al.
Published: (2022)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
by: Man Wang, et al.
Published: (2023)

BCG downregulates PD1 and PD-L1 expression in bladder cancer cells co-cultivated with peripheral blood mononuclear cells
by: Katia R. M. Leite, et al.
Published: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
by: Yuncong Liu, et al.
Published: (2019)

PD‐L1 and PD‐L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules
by: Yue Zhang, et al.
Published: (2022)

PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma
by: Itaru Tojyo, et al.
Published: (2019)

Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors
by: Kemal KÖSEMEHMETOĞLU, et al.
Published: (2017)

Expression of PD-L1 in primary breast carcinoma and lymph node metastases
by: Alice M. Alves, et al.
Published: (2019)

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages
by: Lai CY, et al.
Published: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
by: Jinhua Liu, et al.
Published: (2021)

Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis
by: Fabian Krutzek, et al.
Published: (2022)

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
by: Ai L, et al.
Published: (2020)

PD-1/PD-L1 signaling in JIA synovial regulatory T cell function
by: van Wijk Femke, et al.
Published: (2011)

Hypoxia-induced PD-L1 expression and modulation of muscle stem cell allograft rejection
by: Jacob Raiten, et al.
Published: (2024)

The importance of the PD-1/PD-L1 pathway at the maternal-fetal interface
by: Matyas Meggyes, et al.
Published: (2019)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
by: Ke Zhang, et al.
Published: (2022)

Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer
by: Otília Menyhárt, et al.
Published: (2019)

PD-L1 Expression in Medullary Thyroid Carcinoma and Its Association with Clinicopathological Findings
by: Yasemin KEMAL, et al.
Published: (2022)

PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
by: Sze‐Hwei Lee, et al.
Published: (2022)

Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas
by: Opal L. Reddy, et al.
Published: (2017)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
by: Cunte Chen, et al.
Published: (2021)

Assessment of the Circulating PD-1 and PD-L1 Levels and P53 Expression as a Predictor of Relapse in Pediatric Patients with Wilms Tumor and Hypernephroma
by: Heba A. Sahyon, et al.
Published: (2024)

ICOS/ICOSLG and PD-1 Co-Expression is Associated with the Progression of Colorectal Precancerous- Carcinoma Immune Microenvironment
by: Zhang Y, et al.
Published: (2023)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N)
by: Jing Ma, et al.
Published: (2018)

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
by: Ryunosuke Hoshi, et al.
Published: (2024)

Biomarker recommendation for PD‐1/PD‐L1 immunotherapy development in pediatric cancer based on digital image analysis of PD‐L1 and immune cells
by: Manuel A Silva, et al.
Published: (2020)

IMMUNE RESISTANCE VIA A PD-1/PD-L1 MECHANISM IN GLIOBLASTOMA
by: V.S. KUSHNIROVA, et al.
Published: (2023)